Clinical Trials
-
Principal Investigator:
Alice Lee, MDThe purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United States (US) Food and Drug Administration (FDA) for treating children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib is given by... -
Principal Investigator:
Ilene Fennoy, MDWe are doing this research study to find out about what happens to children who are overweight and how the things we recommend as a part of routine clinical care affect your child. The purpose of this study is to understand what happens to children as a result of being overweight, to link these outcomes to specific clinical measures and to determine how treatment affects the physical and clinical features of overweight or obesity. To achieve this aim we want to formalize our ongoing clinical chart review into a database for our patients. -
Principal Investigator:
Erika Berman Rosenzweig, MDThis research study is being conducted to study pulmonary hypertension and right heart dysfunction based on clinical, imaging, physiological and pathological characteristics. We hope to develop a new classification system and new methods to diagnose and treat pulmonary hypertension. Diagnostic testing includes (listed subsequently): full medical work-up, minimal blood collection, right heart catheterization, echocardiogram, ekg, take home sleep oximetry study, six-minute walk, exercise test, Pulmonary function test, Lung CT, Questionnaires, ventilation/perfusion scan and cardiac MRI. -
Principal Investigator:
Prakash Satwani, MDThe main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma. -
Principal Investigator:
Prakash Satwani, MDThe main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma. -
Principal Investigator:
Alice Lee, MDThis is a Phase 1/2 multicenter study of lenvatinib administered in combination with everolimus inpediatric patients with relapsed or refractory solid tumors, including CNS tumors. The study treatment is considered experimental because lenvatinib is not approved by the United States(US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors. The purpose of this study is to determine the highest safe dose of lenvatinib administered in combination with everolimus. Another objective is to study the effects of this combination of... -
Principal Investigator:
Nobuko Hijiya, MDThis is a Phase 1 multicenter study of Vincristine Sulfate Liposome Injection (Marqibo) in combination with UK ALL R3 induction chemotherapy. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children with acute lymphoblastic leukemia (ALL) who have relapsed. The purpose of this study is to evaluate the toxicities and potential antitumor activity of Marqibo, given in combination with UK ALL R3 induction chemotherapy, in children with refractory ALL. Marqibo will be administered as an intravenous... -
Principal Investigator:
Alice Lee, MDThis is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with tumors, including CNS tumors. Both temozolomide and irinotecan are drugs that are FDA-approved for other indications. The purpose of this study is to... -
Principal Investigator:
Stergios Zacharoulis, MDThe purpose of this study is to learn more about the treatment of children and young adults patient with relapsed (has returned) and progressive medulloblastoma (brain tumor). This study is being done to find out if bevacizumab can be safely given in combination with five study drugs given by mouth, thalidomide, fenofibrate, celecoxib and alternating every three weeks of etoposide and cyclophosphamide. Researchers want to evaluate whether the frequent delivery of low doses of study drugs chemotherapy will work for your cancer, while reducing the toxicity associated with standard dose... -
Principal Investigator:
Nobuko Hijiya, MDThe purpose of this study is to find out if the drugs called Nivolumab and 5-Azacytidine can be given safely in children and young adults with Acute Myeloid Leukemia (AML) which has come back after treatment or has not responded to standard therapy. These drugs are thought to work by turning on genes that limit the growth of cancer cells. The study drugs will be given for 2 courses of chemotherapy duration based on how well the participants will tolerate the study drug and response, each course is 29-36 days long. Treatment for the 2 courses of therapy will last about 2-3 months.